Other languages HBM Holdings Limited

Equities

2142

KYG4403H1002

Market Closed - Hong Kong S.E. Other stock markets 04:09:05 2024-06-07 am EDT			5-day change	1st Jan Change
1.38 ^HKD	+0.73%		-5.48%	-28.87%

May. 23	Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	MT
May. 23	HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Hong Kong Shares Slip Further Down Amidst Interest Rate Reduction, Inflation Worries	May. 23
HBM Holdings Unit, AstraZeneca Sign License, Option Agreement for Targeted Cancer Treatment; Shares Rise 16%	May. 23
Nona Biosciences Co., Ltd and AstraZeneca Enters into License and Option Agreement	May. 22
HBM Holdings Returns to Profitability in 2023	Apr. 02
HBM Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28
HBM Holdings Subsidiary Signs Antibody-Drug Conjugate Discovery Collaboration Deal	Feb. 27
HBM Holdings Gets US FDA Clinical Trial Approval for Anti-Tumor Medication	Jan. 24
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S	Jan. 23
HBM to Swing to 2023 Profit	Jan. 19
HBM Holdings Limited Provides Earnings Guidance for the Year Ended 31 December 2023	Jan. 18
HBM Holdings Limited commences an Equity Buyback Plan for 76,842,891 shares, representing 10% of its issued share capital, under the authorization approved on June 8, 2023.	Dec. 19
HBM Holdings Limited Announces Results of the Phase Iii Clinical Trial, Which Demonstrated That the Efficacy in the Primary and Secondary Endpoints of Batoclimab	Dec. 01
HBM Holdings Limited Announces Executive Changes	23-10-19
HBM Swings to Profit in H1; Shares Up 6%	23-08-29
Harbour BioMed Announces US IND Clearance of Its First ADC Program HBM9033 in Solid Tumors	23-08-28
HBM Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28
Harbour BioMed Appoints Dr. Albert R. Collinson as Independent Non-Executive Director	23-08-08
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	23-07-14
HBM to Swing to H1 Profit Amid 45% Revenue Boost	23-07-13
HBM Holdings Limited Provides Earnings Guidance for the Six Months Ended 30 June 2023	23-07-13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages HBM Holdings Limited

Equities

2142

KYG4403H1002

Other languages

Filters